Heart failure is a common problem and long term monitoring of
heart function accurately in patients has gained increased interest. A study
was carried out in 40 patients to test the safety and feasibility of Titan™
pressure sensor. Titan™ sensor is small, resembling
the CardioMEMS® device . Titan™ is implanted principally in any heart chambers,
recently for the first time modified device of Titan™ was implemented viacatheter in animals and good results were observed. The first study in man on a
new implanted wireless hemodynamic monitor showed favourable results.
Heart failure is a huge health problem. The disease often
follows a similar course; stable in the initial stages but progressive
deterioration develops with exacerbations that eventually lead to recurrent
hospitalization. To begin with, patients usually respond to standard medical
treatment, but the course is unpredictable and in the final stages inotropic
support is often required to preserve life.The possibility of monitoring heart function
more accurately in these patients has gained increasing interest. The ability
to detect a sudden increase in filling pressure would provide early warning of
an imminent exacerbation and enable medical intervention before the development
of clinical symptoms .
There are a few implantable cardiac hemodynamic monitors on
the market, some already in use while others have gone through clinical studies
with successful safety records. These devices can be divided into two
categories; those monitoring pressure of the left side of the heart, and those
on the right.A catheter-based technology with a device introduced into the
pulmonary artery allowing wireless recordings of pulmonary artery pressure and
indirectly pulmonary artery wedge pressure is currently approved by the Food
and Drug Administration. Read more.............
No comments:
Post a Comment